Skip to main content
TipRanks
Go Ultimate75% OFF

CSL (CMXHF) Stock Price & Analysis

89 Followers

CMXHF Stock Chart & Stats

$128.26-$5.56(-4.15%)
At close: 4:00 PM EST
$110$120$130$140Aug 20Sep 8Sep 22Oct 5Oct 19Nov 2Nov 18
Day’s Range
$126.11 - $132.38
52-Week Range
$63.84 - $146.48
Previous Close
$133.82
Volume
N/A
Average Volume (3M)
222
Market Cap
$63.89B
Enterprise Value
$70.67B
Total Cash (Recent Filing)
$1.51B
Total Debt (Recent Filing)
$10.89B
Price to Earnings (P/E)
―
Beta
-0.01
Next Earnings
Feb 09, 2027 (Est.)
Dividend Yield
2.18%

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Positive operating cash flow despite a reported net loss demonstrates that CSL’s core operations continue to generate funds. This supports investment, dividends and buybacks while providing financial flexibility to manage restructuring, capital spending and portfolio remediation over the next several quarters.

Transformation Savings

The transformation program is producing measurable savings ahead of its initial target, with further benefits planned over the next two years. If execution continues, lower operating costs can support margins, fund commercial and R&D reinvestment, and improve earnings quality without relying solely on revenue growth.

Product And Franchise Momentum

Growth from newly launched and specialty products strengthens CSL’s product portfolio beyond mature therapies. ANDEMBRY, HEMGENIX and immunoglobulin momentum can support durable revenue expansion, improve mix and partially offset pressure in weaker franchises as adoption broadens across markets.

Bears Say

Large Impairments And Loss

The scale of impairments and the statutory loss materially weaken recent earnings quality and reduce confidence in the carrying value of acquired assets. Although impairments are non-cash, they signal portfolio underperformance and may constrain management’s flexibility while remediation and restructuring continue.

Structural Vifor Decline

Vifor faces several durable commercial and regulatory pressures rather than a temporary demand fluctuation. Generic competition, lost reimbursement support and the TAVNEOS authorization issue can reduce revenue and earnings, leaving the group more dependent on Behring and successful replacement products.

Albumin Pressure In China

The decline in albumin reflects persistent pricing and market-value pressure in an important geography, not simply a one-period volume disruption. Continued pressure can weigh on Behring’s product mix and gross margin, limiting the benefit of growth in immunoglobulins and newer therapies.

CSL News

CMXHF FAQ

What was CSL’s price range in the past 12 months?
CSL lowest stock price was $63.84 and its highest was $146.48 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $63.89B.
When is CSL’s upcoming earnings report date?
CSL’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 82 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported $2.26 earnings per share for the quarter, missing the consensus estimate of $2.355 by -$0.095.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a semiannual dividend of $1.62 which represents an annual dividend yield of 2.18%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 4.00.
How many shares outstanding does CSL have?
CSL has 479,884,280 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of $2.26 in its last earnings report, missing expectations of $2.355. Following the earnings report the stock price went up 15.502%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in CMXHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology